Tetratherix (TTX.AX) Stock Price

Tetratherix Price

CLOSED
6.19
​
Market closed

Revenue has compounded at 6.4% per year over the past 3 years to 354,756.00 AUD. Tetratherix's net margin stands at -2,627.3%, down from -618.4% several years earlier. Analysts set a median price target of 5.13 AUD, implying 17.1% below the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.

Tetratherix stock price

Access this data via the Eulerpool API

Tetratherix business model & stock analysis

Tetratherix Ltd. engages in the development of a biostealth fluid matrix for regenerative medicine. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2025-06-30. The firm's biomaterial platform is built with polymer programming akin to Medical Lego to form implantable products to solve a range of clinical problems. The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue. Tegenix and TegenEOS products are developed as a carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental, oral and orthopedic applications. TetraDerm products can be used in any surgical incision site to reduce scarring. Tutelix products are intended for use as a spacer to reduce side effects from radiation therapy in prostate cancer. The company has established its manufacturing center in Sydney, featuring a cleanroom production facility.

Frequently asked questions about Tetratherix

Analysts currently set an average price target of 5.13 AUD for the Tetratherix stock (median: 5.13 AUD), implying -17.1 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Tetratherix stock: 5 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Tetratherix share trades at 3.86 EUR (6.19 AUD).

The revenue of Tetratherix is 354,756.00 AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Tetratherix is -9.32 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Tetratherix is currently -35.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Tetratherix stock.

The price-to-sales ratio (P/S) of Tetratherix is currently 925.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Tetratherix stock.

The Eulerpool Quality Score for Tetratherix is 3/10.

The ISIN of Tetratherix is AU0000400574. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Tetratherix is TTX.AX. The ticker symbol is used to trade Tetratherix shares on the stock exchange.

Fair ValueTerminal
6.44 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Jun 30, 2025
ISIN
AU0000400574
Cusip
Q9022E106
Market capitalization
168.24 M AUDMicro Cap
52-Week Range
PEG
-16.43
P/E ratio
P/Ee 2027
-76.54
P/Ee 2028
-93.13
P/Ee 2029
-71.83
P/Se
37.31
EV/EBIT
—
P/B Ratio
5.14
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.92 %
Last updated Oct 14, 2026, 1:20 AM

Tetratherix Peer Group